Axsome Malta v. Alkem Laboratories: Solriamfetol Generic Patent Dispute Ends in Stipulated Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Axsome Malta, Ltd. v. Alkem Laboratories, Ltd. |
| Case Number | 2:25-cv-14694 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Aug 15, 2025 – Feb 19, 2026 188 days |
| Outcome | Stipulated Dismissal (No Merits Ruling) |
| Patents at Issue | |
| Accused Products | Alkem’s generic solriamfetol oral tablets (generic versions of Sunosi®) |
Case Overview
The Parties
⚖️ Plaintiff
An affiliate of Axsome Therapeutics, Inc., a commercial-stage CNS biopharmaceutical company marketing Sunosi® (solriamfetol) for excessive daytime sleepiness.
🛡️ Defendant
A major Indian generic pharmaceutical manufacturer with a significant U.S. market presence, actively pursuing ANDA filings.
Patents at Issue
This case involved four U.S. patents protecting Axsome’s solriamfetol oral tablet formulations. These patents collectively cover formulation, dosing, and/or method-of-use claims related to the drug. Patent numbers can be verified directly through the USPTO Patent Full-Text Database and the FDA Orange Book.
- • US12263145B2 — Solriamfetol oral tablet formulations
- • US12194016B2 — Dosing regimens for solriamfetol
- • US12102609B2 — Methods of using solriamfetol
- • US12318362B2 — Further solriamfetol formulation claims
Developing a similar drug formulation?
Check if your generic solriamfetol formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded with a **stipulated voluntary dismissal without prejudice**, entered by joint agreement of Axsome Malta, Ltd., Axsome Therapeutics, Inc., and Alkem Laboratories, Ltd. No damages were awarded, and no injunctive relief was granted or denied on the merits. Specific settlement terms were not disclosed in the public record.
Verdict Cause Analysis
The infringement action was brought under the Hatch-Waxman Act, where Alkem’s ANDA paragraph IV certification constituted a technical act of infringement sufficient to trigger litigation. The case did not proceed far enough to generate substantive rulings on claim construction, patent validity (e.g., obviousness under 35 U.S.C. § 103, enablement under § 112), or literal infringement versus doctrine of equivalents.
The absence of any court ruling on the merits means the asserted patents — US12263145B2, US12194016B2, US12102609B2, and US12318362B2 — remain valid and enforceable as issued. Alkem did not secure a judicial finding of invalidity or non-infringement, which carries strategic weight for Axsome in any subsequent generic challenges.
Legal Significance
The dismissal **without prejudice** is legally significant: Axsome preserves the right to re-assert these patents against Alkem should circumstances change, such as a renewed ANDA filing, product launch, or reformulated generic submission. The U.S. District Court for the District of New Jersey’s retained jurisdiction clause further signals that a negotiated arrangement — potentially a settlement agreement with future enforcement provisions — likely underlies the dismissal.
This case adds to the substantial body of New Jersey Hatch-Waxman dismissals reflecting negotiated resolutions, consistent with data showing that approximately 70–80% of paragraph IV litigations settle before trial.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in generic pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications for solriamfetol and CNS drugs.
- View all 4 patents asserted in this case
- See key players in CNS drug patents
- Understand formulation claim patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug or API.
- Input your generic formulation or API description
- AI identifies potentially blocking drug patents
- Get actionable risk assessment report
High Risk Area
Solriamfetol formulation and dosing
4 Asserted Patents
Specific to solriamfetol
Design-Around Options
May be available for formulation
✅ Key Takeaways
Stipulated dismissal without prejudice preserves full re-assertion rights — counsel should ensure retained jurisdiction clauses are drafted precisely.
Search related case law →Four-patent assertion strategies in Hatch-Waxman litigation increase settlement leverage substantially.
Explore precedents →Frequently Asked Questions
Four U.S. patents were asserted: US12263145B2, US12194016B2, US12102609B2, and US12318362B2 — all covering aspects of solriamfetol oral tablet formulations and related methods.
The parties entered a joint stipulation of dismissal without prejudice under FRCP 41(a)(1)(A)(ii), with no costs awarded and no merits ruling issued by the court.
The dismissal without prejudice preserves Axsome’s ability to re-assert these patents against Alkem or others; it provides no validity or infringement findings that other generic challengers could leverage as persuasive precedent.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Patent and Trademark Office (USPTO) Patent Full-Text Database
- FDA Orange Book
- U.S. District Court for the District of New Jersey — Case 2:25-cv-14694
- Cornell Legal Information Institute — Federal Rules of Civil Procedure 41(a)(1)(A)(ii)
- Saul Ewing LLP (Legal Counsel)
- Stone Conroy LLC (Legal Counsel)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.